Chembio takes rapid HIV tests to the US
This article was originally published in Clinica
Executive Summary
Paving its entry into the lucrative US HIV testing market, Chembio Diagnostics has gained FDA approval for its rapid HIV tests. Clearance of its Sure Check HIV 1/2 and HIV 1/2 Stat-Pak tests will allow the company to tap into a US rapid HIV test professional market that it believes will exceed $50m within the next couple of years. Chembio is currently in discussions with a partner to market the products in the US.
You may also be interested in...
Health And Wellness Trademark Review 1 December, 2020
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Ipsen CEO Outlines Strategy For Long-Term Success
While analysts are struggling to look further than generic competition facing the French firm's best-seller Somatuline, new chief David Loew tells Scrip that intelligent lifecycle management and focused external deals will drive Ipsen's growth.
US Startup Ignites Consumer Health Portfolio Build With North American Rights To ThermaCare
Bridges Consumer Healthcare launched by former Sanofi executives gets its first brand by acquiring North American rights to Pfizer’s ThermaCare HeatWraps brand. Pfizer divested the brand so European regulators would give antitrust clearance to its consumer JV with GSK.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: